Department: Comparative Biomedical Sciences

Campus: Hawkshead

Research Groups: Antimicrobial Resistance, IRLFS (Research Programme), Cardiovascular and Renal Biology, Brain Health and Behaviour, CPCS (Research Programme)

Clinical Groups: Small Animal Anaesthesia, Large Animal Anaesthesia

Research Centres: RVC Quantitative Biology Resource, Clinical Investigation Centre

Ludovic is a diplomate of the ECVAA and ECVPT. He is currently Professor in Veterinary Clinical Pharmacology and Anaesthesia. He is co-head of the RVC anaesthesia service. Ludovic has a passion for clinically applied research in the field of inflammation and pain and in the field of veterinary antimicrobial drugs.

Ludovic graduated from the École Nationale Vétérinaire d'Alfort (Paris, France) in 2001, where he completed a two-year small animal internal medicine internship. He then completed a 3-year anaesthesia residency at the Royal Veterinary College (RVC), London, UK where he gained his European Diploma of Veterinary Anaesthesia and Anaesthesia in 2006.

Ludovic completed his pharmacology PhD at the RVC in 2010 on the roles of cyclooxygenase (COX) isoenzymes in the regulation of inflammation and the renal function in the cat (supervised by Professor Jonathan Elliott and Professor Peter Lees and Dr. Jon King).

Ludovic has been back in the clinics as a senior anesthetist since the end of his PhD. He is currently Professor in Veterinary Clinical Pharmacology and Anaesthesia.

Ludovic gained the European Diploma in Veterinary Anaesthesia and Analgesia in 2006 and his European Diploma in Veterinary Pharmacology and Toxicology in 2014.

Ludovic's main research interests is pharmacology of analgesics, in particular NSAIDs and other drugs in species of veterinary interest (cats, dogs, horses, calves but also more exotic species such as emus or salamanders). He is developing research programs in pharmacology and pain management (acute and chronic), particularly in the area of pharmacokinetics and mathematical modeling (PK-PD).

Ludovic is promoting the use of pharmacometrics to help resolve clinical questions at the level of the invidual animal or for more global questions, as in the field of antimicrobial use and resistance. Ludovic is in the steering committee of VetCAST, the veterinary section of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).  Ludovic is the leader of the workpackage on Antimicrobials in the One Health Poultry Hub (onehealthpoultry.org).

 

Ludovic collaborates in his research with colleagues from the RVC (Peter Lees, Jonathan Elliott, Holger Volk, Siobhan Abeyesinghe and others) and has established solid research or business relationships with external companies as detlaDOT Ltd, Transpharmation and Triveritas.

Ludovic is striving to expand the RVC analytical laboratory to support veterinary a therapeutic drug monitoring service and drug development schemes in collaboration with deltaDOT Ltd. A iohexol test is already avaialble to monitor glomerular filtration rate (GFR) in dogs and cats.

Current PhD students:

Mr. Andrew Mead: PK PD informed clinical breakpoint determination for colistin in chicken to limit emergence of resistance and improve One Health antimicrobial sustainability

Mr. Stefano Azzariti: Bridging the preclinical/clinical gap for optimisation of efficacy and avoidance of resistance for fluoroquinolones, application to canine pyoderma

Past PhD students:
Miss Hannah Kenward (co-supervisor: Jonathan Elliott and Karine Savary-Bataille, Zoetis):"Objectives measures of Nausea in the Dog". BBSRC CASE award.

Miss  Sandra Sanchis Mora (co-supervisor Siobhan Abeyesinghe, Holger Volk and Transpharmation Ltd): "Multidisciplinary approach for improving diagnosis and treatment of spontaneous canine neuropathic pain". Click on the link below for further details:
http://www.rvc.ac.uk/Postgraduate/Research/PhD/PelligandMR2012.cfm
 

Research publications:

Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs.
Pelligand L, Guillot E, Geneteau A, Guyonnet J, Magnier R, Elliott J, Peyrou M, Jacobs M.
Front Vet Sci. 2020 Apr 28;7:151. doi: 10.3389/fvets.2020.00151.

Semi-Mechanistic Modeling of Florfenicol Time-Kill Curves and in silico Dose Fractionation for Calf Respiratory Pathogens. Pelligand L., Lees P., Sidhu P.K., Toutain P-L. Front. Microbiol., 11 June 2019 | https://doi.org/10.3389/fmicb.2019.01237

VetCAST Method for Determination of the Pharmacokinetic-Pharmacodynamic Cut-Off Values of a Long-Acting Formulation of Florfenicol to Support Clinical Breakpoints for Florfenicol Antimicrobial Susceptibility Testing in Cattle. Toutain P.-L., Sidhu P.K., Lees P., Rassouli A., Pelligand L.  Front. Microbiol., 12 June 2019 | https://doi.org/10.3389/fmicb.2019.01310

Relating neuromuscular control to functional anatomy of limb muscles in extant archosaurs. Cuff A.R., Daley M.A., Michel K.B., Allen V.R., Lamas L.P., Adami C., Monticelli P., Pelligand L., Hutchinson J.R. J Morphol. 2019 May;280(5):666-680. doi: 10.1002/jmor.20973. Epub 2019 Mar 8.

Systemic glucocorticoid usage in dogs under primary veterinary care in the UK: prevalence and risk factors. Elkholly D.A., O'Neill D., Wright A.K., Mwacalimba K., Nolan L.S., Pavlock A., Pelligand L., Church D., Brodbelt D.C. Vet Rec. 2019 May 10. pii: vetrec-2018-105220. doi: 10.1136/vr.105220.

A double-blinded randomised dietary supplement crossover trial design to investigate the short-term influence of medium chain fatty acid (MCT) supplement on canine idiopathic epilepsy: study protocol. Berk B.A., Packer R.M.A., Law T.H., Wessmann A., Bathen-Nöthen A., Jokinen T.S., Knebel A., Tipold A., Pelligand L., Volk H.A., BMC Vet Res. 2019 May 30;15(1):181. doi: 10.1186/s12917-019-1915-8.

Sedative and antinociceptive effects of different detomidine constant rate infusions, with or without methadone in standing horses. Gozalo-Marcilla M., Luna S. P. L., Moreira da Silva R. , Crosignani N. , Lopes N. P., , Pelligand L., Taylor P. M.,  Equine Vet J. 2019 Jul;51(4):530-536. doi: 10.1111/evj.13054. Epub 2018 Dec 18.

Pharmacodynamics of tetracycline, oxytetracycline and doxycycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida in three growth media. Mead A., Lees P., Mitchell J., Rycroft A., Standing J., Toutain P.-L., Pelligand L. J Vet Pharmacol Ther. 2019 Jan;42(1):52-59. doi: 10.1111/jvp.12719. Epub 2018 Sep 28.

Characterisation of the in vivo interactions between detomidine and methadone in horses: Pharmacokinetic and pharmacodynamic modelling. Gozalo-Marcilla M., Luna S. P. L., Moreira da Silva R. , Crosignani N. , Lopes N. P., Taylor P. M., Pelligand L. . Equine Vet J. 2019 Jul;51(4):517-529.

Faculty Perception of an Embedded Research Project in the Undergraduate Veterinary Curriculum. Cehrs E., Pelligand L., Weller R., . Journal of Veterinary Medical Education, J Vet Med Educ. 2019 Apr 22:1-7. doi: 10.3138/jvme.0318-028r1

Evaluation of the dynamic predictors of fluid responsiveness in dogs receiving goal-directed fluid therapy. Drozdzynska MJ, Chang YM, Stanzani G, Pelligand L. Vet Anaesth Analg. 2017 Jun 17

Sedative and antinociceptive effects of different combinations of detomidine and methadone in standing horses. Gozalo-Marcilla M, Luna SP, Crosignani N, Filho JNP, Possebon FS, Pelligand L, Taylor PM. Vet Anaesth Analg. 2017 Sep;44(5):1116-1127.

Evaluation of analgesic effect and absorption of buprenorphine after buccal administration in cats with oral disease. Stathopoulou TR, Kouki M, Pypendop BH, Johnston A, Papadimitriou S, Pelligand L. J Feline Med Surg. 2017 Sep

Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. Kenward H, Elliott J, Lee T, Pelligand L. BMC Vet Res. 2017 Aug 16;13(1):244.

Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida. Lees P, Potter T, Pelligand L, Toutain PL. J Vet Pharmacol Ther. 2017

Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling. Dorey L, Pelligand L, Lees P. BMC Vet Res. 2017 Jul 1;13(1):209

Development and initial validation of a sensory threshold examination protocol (STEP) for phenotyping canine pain syndromes. Sanchis-Mora S, Chang YM, Abeyesinghe S, Fisher A, Volk HA, Pelligand L. Vet Anaesth Analg. 2017 May;44(3):600-614

Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida. Dorey L, Pelligand L, Cheng Z, Lees P. PLoS One. 2017 May 26;12(5)

Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats. Doodnaught GM, Monteiro BP, Benito J, Edge D, Beaudry F, Pelligand L, Steagall P. PLoS One. 2017 Apr 26;12(4):e0176443. doi: 10.1371/journal.pone.0176443. eCollection 2017

Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida. Dorey L, Pelligand L, Cheng Z, Lees P. J Vet Pharmacol Ther. 2017 Jan 16. doi: 10.1111/jvp.12385. [Epub ahead of print]

Comparison of standardised versus non-standardised methods for testing the in vitro potency of oxytetracycline against Mannheimia haemolytica and Pasteurella multocida. Lees P, Illambas J, Pelligand L, Toutain PL. Vet J. 2016 Dec;218:60-64. doi: 10.1016/j.tvjl.2016.11.006. Epub 2016 Nov 17.

A large potentiation effect of serum on the in vitro potency of tulathromycin against Mannheimia haemolytica and Pasteurella multocida. Lees P, Illambas J, Potter TJ, Pelligand L, Rycroft A, Toutain PL. J Vet Pharmacol Ther. 2016 Nov 27. doi: 10.1111/jvp.12372. [Epub ahead of print]

Dogs attending primary-care practice in England with clinical signs suggestive of Chiari-like malformation/syringomyelia. Sanchis-Mora S, Pelligand L, Thomas CL, Volk HA, Abeyesinghe SM, Brodbelt DC, Church DB, Thomson PC, McGreevy PD, O'Neill DG. Vet Rec. 2016 Oct 29;179(17):436. doi: 10.1136/vr.103651. Epub 2016 Aug 17.

Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats. Pelligand L, Soubret A, King JN, Elliott J, Mochel JP. CPT Pharmacometrics Syst Pharmacol. 2016 Oct 22.

Dogs attending primary-care practice in England with clinical signs suggestive of Chiari-like malformation/syringomyelia. Sanchis-Mora S, Pelligand L, Thomas CL, Volk HA, Abeyesinghe SM, Brodbelt DC, Church DB, Thomson PC, McGreevy PD, O'Neill DG. Vet Rec. 2016 Oct 29;179(17):436.

Factors Influencing the Relationship Between the Dose of Amlodipine Required for Blood Pressure Control and Change in Blood Pressure in Hypertensive Cats. Bijsmans ES, Doig M, Jepson RE, Syme HM, Elliott J, Pelligand L. J Vet Intern Med. 2016 Sep;30(5):1630-1636.

Veterinary Medicine Needs New Green Antimicrobial Drugs. Toutain PL, Ferran AA, Bousquet-Melou A, Pelligand L, Lees P. Front Microbiol. 2016 Aug 3;7:1196.

Standard PK/PD concepts can be applied to determine a dosage regimen for a macrolide: the case of tulathromycin in the calf. Toutain PL, Potter T, Pelligand L, Lacroix M, Illambas J, Lees P. J Vet Pharmacol Ther. 2016 Aug 8. doi: 10.1111/jvp.12333. [Epub ahead of print]

Effect of Cyclooxygenase(COX)-1 and COX-2 inhibition on furosemide-induced renal responses and isoform immunolocalization in the healthy cat kidney. Pelligand L, Suemanotham N, King JN, Seewald W, Syme H, Smith K, Lees P, Elliott J. BMC Vet Res. 2015 Dec 3;11:296

Diagnosis and treatment of canine neuropathic pain. Sanchis-Mora S, Pelligand L, Volk HA, Abeyesinghe SM. Vet Rec. 2015 Nov 7;177(18):470. doi: 10.1136/vr.h5927.

Neutrophil Gelatinase-Associated Lipocalin in Dogs With Sepsis Undergoing Emergency Laparotomy: A Prospective Case-Control Study. Cortellini S, Pelligand L, Syme H, Chang YM, Adamantos S. J Vet Intern Med. 2015 Nov-Dec;29(6):1595-602. doi: 10.1111/jvim.13638. Epub 2015 Sep 29.

Pharmacokinetic/pharmacodynamic integration and modelling of amoxicillin for the calf pathogens Mannheimia haemolytica and Pasteurella multocida. Lees P, Pelligand L, Illambas J, Potter T, Lacroix M, Rycroft A, Toutain PL. J Vet Pharmacol Ther. 2015 Oct;38(5):457-70. doi: 10.1111/jvp.12207. Epub 2015 Feb 9.

Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation
Pelligand L., King J.N., Hormabazal V., Toutain P.L., Elliott J., Lees P:
JVPT, 2014 Mar 15. doi: 10.1111/jvp.12107.

Assessment of low-dose cisplatin as a model of nausea and emesis in beagle dogs, potential for repeated administration. Kenward H, Pelligand L, Elliott J. Exp Brain Res. 2014 May 4. [Epub ahead of print]

Pharmacokinetic-pharmacodynamic modelling of intravenous buprenorphine in conscious horses. Love EJ, Pelligand L, Taylor PM, Murrell JC, Sear JW. Vet Anaesth Analg. 2014 Apr 16. doi: 10.1111/vaa.12165. [Epub ahead of print]

 

 

 

 

 

Ludovic is teaching pharmacology to undergraduates for the BVSc2 courses.

 

 

Ludovic is joint-head of the RVC anaesthesia /analgesia service in the different hospitals (QMH, BSAH, Equine Referral Centre). He enjoys running the busy service, teaching students and anaesthesia residents and dealing with anaesthetic challenges.

 

International working group membership:

Member of the Therapeutic  Guidelines Group (TGG) of the World Small Animal Veterinary Association (WSAVA)

Invited member of the Comité Analyse et Maîtrise du Risque, Societe Francaise Anesthesie et Reanimation (SFAR)

Core founding member and the webmaster of the Animal Health Modelling and Simulation Society.   The objectives of this new society are explained in the following paper::    Mochel JP, Gabrielsson J, Collard W, Fink M, Gehring R, Laffont C, Liu Y, Martin-Jimenez T, Pelligand L, Steimer JL, Toutain PL, Whittem T, Riviere J.: Animal Health Modeling & Simulation Society: a new society promoting model-based approaches in veterinary pharmacology. J Vet Pharmacol Ther. 2013 May 29. doi: 10.1111/jvp.12060. [Epub ahead of print]. PMID: 23713757

 

  • Action project on Alternatives to Veterinary Antimicrobials (AVANT)

    Professor of Veterinary Bacteriology Luca Guardabassi is the coordinator of a large EU Innovation Action project on Alternatives to Veterinary Antimicrobials (AVANT) involving 8 industries, 5 universities and the Federation of Veterinarians of Europe.

    AVANT is a multi-actor inter-sectorial project aimed at developing alternatives to antimicrobials for the management of bacterial infections in pigs, especially diarrhoea during the weaning period, as the major indication for antimicrobial use in livestock in Europe. 


  • Optimized dosing regimens for the combinations of sulphonamides and trimethoprim in veterinary medicine (SulTAn)

    To fill the gaps related to the pharmacokinetics of Trimethoprim and Sulphonamides, and to the pharmacodynamics (PD) of their interaction on veterinary pathogens across multiple animal species.

    This project will focus on the combination of different S with TMP in veterinary medicine and will aim at determining the needed adjustments or revisions to optimize TMPS dosage regimens in domestic animal species.


  • PK/PD informed clinical breakpoint determination for colistin in chicken to limit emergence of resistance and improve One Health antimicrobial sustainability

    This project aims to evaluate the impact of colistin use on antimicrobial resistance and rationalise dosing through a combination of in vivo pharmacokinetic (PK) dose studies, in vitro pharmacodynamic (PD) and antimicrobial susceptibility testing, and advanced in silico PK/PD modelling.

    To maintain colistin as an essential antimicrobial for both human and veterinary use, recent and reliable data regarding the pharmacokinetics (PK) and pharmacodynamics (PD) at the clinical dose in poultry, and its impact on the potential selection of resistance is required to inform application and policy.


  • Quality of veterinary oral formulations of amoxicillin/clavulanic acid in World Small Animal Veterinary Association (WSAVA) member countries

    The RVC team is researching the deficits of amoxicillin/clavulanic acid (AMC) in tablet form, following more general concerns about substandard or falsified veterinary medicines being sold in some settings.

    The aim is to detect types and frequency of deficits in the quality of veterinary oral formulations of AMC and identify regional trends including differences between countries or between geographical areas within the same country.

    Lack of efficacy due to SF veterinary products may be life-threatening in the case of antimicrobials drugs or vaccines. Furthermore, SF antimicrobial products are likely to expose sick animals to sub therapeutic levels and contribute to treatment failure and antimicrobial resistance.


  • Temporal dynamic resistance of skin and gastrointestinal bacteria in canine pyoderma

    Temporal dynamic resistance of skin and gastrointestinal bacteria in canine pyoderma: Comparison between marbofloxacin and pradofloxacin in an investigator-blinded randomised interventional study. Pharmacokinetic data will be combined with MIC distribution together with the relationship between exposure and dynamic of bacterial kill modelled will be used to propose clinical breakpoints (highest MIC value considered “sensitive”) for fluoroquinolones in canine pyoderma.


  • UK Research and Innovation (UKRI) Global Challenges Research Fund (GCRF) One Health Poultry Hub

    With integrated streams of social, economic, biological, mathematical and policy-led research, we are co-producing detailed knowledge on the biological, structural and socio-economic factors that shape networks of chicken production and distribution. The RVC-led UKRI GCRF One Health Poultry Hub brings together leading laboratory, clinical, veterinary and social scientists, as well as skilled communications experts, programme support staff and external stakeholders.  


Top of page